Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 8, 2015, Pages 337.e7-337.e14

  Lughezzani, Giovanni ^a   Lazzeri, Massimo ^a   Buffi, Nicolò Maria ^a   Abrate, Alberto ^a   Mistretta, Francesco Alessandro ^b   Hurle, Rodolfo ^a   Pasini, Luisa ^a   Castaldo, Luigi ^a   Zandegiacomo De Zorzi, Silvia ^a   Peschechera, Roberto ^a   Fiorini, Girolamo ^a   Taverna, Gianluigi ^a   Casale, Paolo ^a   Guazzoni, Giorgio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Biochemical recurrence; Prostate cancer; Prostate health index; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER RECURRENCE; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATECTOMY; RECURRENCE RISK; ROBOT ASSISTED RADICAL PROSTATECTOMY; ROBOT ASSISTED SURGERY; SEMINAL VESICLE; TUMOR BIOPSY; TUMOR INVASION; COHORT ANALYSIS; PATHOLOGY; PREOPERATIVE PERIOD; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84937512633     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.05.007     Document Type: Article

References (19)

1. Hull G.W., Rabbani F., Abbas F., Wheeler T.M., Kattan M.W., Scardino P.T. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167:528-534.
2. Porter C.R., Kodama K., Gibbons R.P., Correa R., Chun F.K., Perrotte P., et al. 25-Year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006, 176:569-574.
3. Koulikov D., Mohler M.C., Mehedint D.C., Attwood K., Wilding G.E., Mohler J.L. Low detectable prostate specific antigen after radical prostatectomy-treat or watch?. J Urol 2014, 192:1390-1396.
4. Dev H.S., Wiklund P., Patel V., Parashar D., Palmer K., Nyberg T., et al. Surgical margin length and location affect recurrence rates after robotic prostatectomy. Urol Oncol 2015, 33:109. e7-13.
5. Walz J., Chun F.K., Klein E.A., Reuther A., Saad F., Graefen M., et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009, 181:601-607. [Discussion: 7-8].
6. Pinto F., Prayer-Galetti T., Gardiman M., Sacco E., Ciaccia M., Fracalanza S., et al. Clinical and pathological characteristics of patients presenting with biochemical progression after radical retropubic prostatectomy for pathologically organ-confined prostate cancer. Urol Int 2006, 76:202-208.
7. Lughezzani G., Briganti A., Karakiewicz P.I., Kattan M.W., Montorsi F., Shariat S.F., et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010, 58:687-700.
8. Miyake H., Fujisawa M. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. Int J Urol 2013, 20:301-311.
9. Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol. 2014. [Epub ahead of print].
10. Guazzoni G., Lazzeri M., Nava L., Lughezzani G., Larcher A., Scattoni V., et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012, 61:455-466.
11. Semjonow A., Köpke T., Eltze E., Darte C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010, 47:926-928.
12. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
13. van der Kwast T.H., Amin M.B., Billis A., Epstein J.I., Griffiths D., Humphrey P.A., et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011, 24:16-25.
14. Mottet N, Bastian PJ, Bellmunt J, van den Bergh RCN, Mason MD, Matveev V, et al. EAU guidelines on prostate cancer. 2014, http://uroweb.org/guideline/prostate-cancer/.
15. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000, 163:1632-1642.
16. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
17. Ross P.L., Gerigk C., Gonen M., Yossepowitch O., Cagiannos I., Sogani P.C., et al. Comparisons of nomograms and urologists[U+05F3] predictions in prostate cancer. Semin Urol Oncol 2002, 20:82-88.
18. Cooperberg M.R., Simko J.P., Cowan J.E., Reid J.E., Djalilvand A., Bhatnagar S., et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013, 31:1428-1434.
19. Sommariva S., Tarricone R., Lazzeri M., Ricciardi W., Montorsi F. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 2014, [Epub Ahead of Print].